Page 1

EX - 99.1 2 d31719dex991.htm EX - 99.1 Exhibit 99.1 MiMedx Announces First Quarter 2021 Financial and Operating Results First Quarter Net Sales of $ 60.0 Million Advancing Innovative Late - Stage Musculoskeletal Pipeline with Data Readouts Expected in Q3 2021 Company to Host Conference Call on April 29 , 2021 at 8:30 AM ET MARIETTA , Ga . , April 28 , 2021 - MiMedx Group , Inc. ( Nasdaq : MDXG ) ( " MiMedx " or the " Company " ) , an industry leader in utilizing amniotic tissue as a platform for regenerative medicine , today announced the filing of its first quarter 2021 Form 10 - Q for the period ended March 31 , 2021 . Timothy R. Wright , MiMedx Chief Executive Officer , commented , “ The first quarter marked significant progress in advancing our clinical programs , including planned investments in additional preclinical evidence to support both our pipeline and core business . One of our top priorities this year is to continue the acceleration of our late - stage clinical programs , and we look forward to announcing top - line results from our three Investigational New Drug ( IND ) studies in Plantar Fasciitis , Achilles Tendonitis , and Knee Osteoarthritis later this summer . On the commercial front , I am pleased to report that we are on track with the continued recruitment of highly - skilled field personnel to grow our core business . Looking ahead , we remain committed to executing our long - term , strategic initiatives that are designed to deliver meaningful value to all our stakeholders , and are steadfast in our mission to improve people's health and lives through evidence - based regenerative technologies that make healing possible . " First Quarter 2021 and Recent Operating Highlights : • • Completed last patients ' final clinical visits in two Phase 3 studies of AmnioFix® Injectable ( micronized dehydrated Human Amnion Chorion Membrane ( mdHACM ) ) as a potential treatment for Plantar Fasciitis and Achilles Tendonitis Announced completion of all clinical effectiveness endpoint visits in a Phase 2B study of mdHACM as a potential treatment for Knee Osteoarthritis Added Dirk Stevens , Ph.D. , an accomplished regulatory leader with more than 35 years of strategic leadership experience in quality management and regulatory compliance , as Senior Vice President , Quality Assurance and Regulatory Affairs Awarded a Group Purchasing Agreement for the Company's amniotic tissue portfolio from Premier® Inc.'s Synergizing for Unparalleled Results in Procurement and Strategic Sourcing ( SURPASSTM ) purchasing program Received notification from the U.S. Food and Drug Administration ( FDA ) that the Company's IND for the use of AmnioFix® Injectable ( mdHACM ) in Chronic Cutaneous Ulcers was accepted as filed Appointed Phyllis Gardner , M.D. , a professor of medicine at the Stanford University School of Medicine and distinguished business leader , to the Company's Board of Directors Received notification of expanded coverage by a large national commercial payor for EpiCord® as a medically necessary option in the treatment of Diabetic Foot Ulcers